Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NantCell completes second round, gets $30mm from Celgene

Executive Summary

Oncology immunotherapy developer NantCell Inc. (a NantHealth company) raised $30mm through a crossover investment from Celgene. This is the second such round for NantCell and Celgene; NantCell was founded in 2015 with an initial $75mm investment by Celgene, which now holds a 2.8% stake. Announcement of the funding came shortly after Celgene revealed that it would be acquired by BMS for $74bn.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies